Rockwell Medical Added to Russell Microcap Index
June 26 2023 - 6:00AM
Business Wire
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a
healthcare company that develops, manufactures, commercializes, and
distributes a portfolio of hemodialysis products to dialysis
providers worldwide, today announced that the Company was added to
the Russell Microcap® Index.
The newly reconstituted index took effect after the market close
on Friday, June 23, 2023. Membership in the Russell Microcap® Index
remains in place for one year and means automatic inclusion in the
appropriate growth and value style indexes. FTSE Russell determines
membership for its Russell indexes primarily by objective,
market-capitalization rankings and style attributes.
"FTSE Russell's annual reconstitution process is essential for
turnaround companies like Rockwell Medical, which rehabilitated its
focus and business strategy and made significant strides over the
last year resulting in a higher total market capitalization," said
Mark Strobeck, Ph.D., President and CEO of Rockwell Medical. "We
continue to grow our business and improve our financial outlook
through increased revenue, improved gross profit, and reduced
operating expenses. We have rebuilt credibility with retail and
institutional investors and believe that collectively, this is
driving increased interest in, and value for, our company."
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $12.1 trillion in
assets are benchmarked against Russell’s U.S. indexes. Russell
indexes are part of FTSE Russell, a leading global index provider.
For more information on the Russell Microcap® Index and the Russell
indexes reconstitution, go to the “Russell Reconstitution” section
on the FTSE Russell website.
About Rockwell Medical
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company
that develops, manufactures, commercializes, and distributes a
portfolio of hemodialysis products for dialysis providers
worldwide. Rockwell Medical's mission is to provide dialysis
clinics and the patients they serve with the highest quality
products supported by the best customer service in the industry.
Rockwell is focused on innovative, long-term growth strategies that
enhance its products, its processes, and its people, enabling the
Company to deliver exceptional value to the healthcare system and
provide a positive impact on the lives of hemodialysis patients.
Hemodialysis is the most common form of end-stage kidney disease
treatment and is usually performed at freestanding outpatient
dialysis centers, at hospital-based outpatient centers, at skilled
nursing facilities, or in a patient’s home. Rockwell Medical's
products are vital to vulnerable patients with end-stage kidney
disease, and the Company is relentless in providing unmatched
reliability and customer service. Rockwell Medical is the second
largest supplier of acid and bicarbonate concentrates for dialysis
patients in the United States and has the vision of becoming the
leading global supplier of hemodialysis concentrates. Certified as
a Great Place to Work® in 2023, Rockwell Medical is Driven to
Deliver Life-Sustaining Dialysis SolutionsTM. For more information,
visit www.RockwellMed.com.
Forward-Looking Statements
Certain statements in this press release may constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as, "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue," "could,"
"can," "would," "develop," "plan," "potential," "predict,"
"forecast," "project," "intend," "look forward to," "remain
confident," “are determined,” “are on track,” “are resolute in our
vision,” "work to," "drive towards," or the negative of these
terms, and similar expressions, or statements regarding intent,
belief, or current expectations, are forward looking statements.
There can be no assurance that Rockwell will grow its business,
improve its financial outlook through increased revenue, improved
gross profit, and reduced operating expenses, or drive increased
interest in and value for the company. While Rockwell Medical
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties (including, without limitation, those set
forth in Rockwell Medical's SEC filings), many of which are beyond
our control and subject to change. Actual results could be
materially different. Risks and uncertainties include, but are not
limited to those risks more fully discussed in the "Risk Factors"
section of our Annual Report on Form 10-K for the year ended
December 31, 2022, as such description may be amended or updated in
any future reports we file with the SEC. Rockwell Medical expressly
disclaims any obligation to update our forward-looking statements,
except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230626458824/en/
Heather R. Hunter SVP, Chief Corporate Affairs Officer (248)
432-1362 IR@RockwellMed.com
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Apr 2024 to May 2024
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From May 2023 to May 2024